Drugs / TT-816
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05525455 | Aug 2022 → Sep 2023 | cancer | Teon Therapeutics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-01 | Teon Therapeutics, Inc. | Regulatory Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816 teontherapeutics.com ↗
The IND enables Teon to initiate its planned Phase 1/2 clinical trial designed to assess the dosing, tolerability and safety of TT-816 in patients with advanced cancers as a monotherapy and in combination with existing standard of care anti-PD-1 checkpoint inhibitors. |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TT-816 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525455 ↗ |
| Action | Inhibit | “cannabinoid CB2 receptor antagonist” NCT05525455 ↗ |
| Route | Oral | “oral” NCT05525455 ↗ |